Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib in EGFR-mutated Unresectable Stage III NSCLC (APPROACH)
NCT04841811Phase 3Active, not recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of almonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Association of Clinical Trials. Primary endpoints: Objective Response Rate at 8 weeks and Event Free Survival rate at 18 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04841811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841811.